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Dear Editor, 
In their network meta-analyses (NMAs) of treatments for ulcerative colitis (UC), Singh et al1 did 
not take into account a complication associated with studies that re-randomized patients for the 
maintenance phase: differential carryover effects from induction can bias the results. In those 
studies, patients who responded to induction were re-randomized to maintenance treatments that 
included placebo. If, however, carryover effects from induction differ substantially among active 
treatments, the effects of those treatments, relativ  to placebo, are not comparable.  
Placebo rates in the re-randomized maintenance studie  suggest that ustekinumab provided 
greater carryover effects from induction than the other treatments. In the biologic-non-failure 
populations, 31.0% in the ustekinumab study,2 20.5% in the vedolizumab study,3 15.6% in the 








responding to induction and receiving placebo maintenance (Chi-squared test, p<0.001). In the 
biologic-failure populations, 17.0% in the ustekinumab study, 11.2% in the tofacitinib study, and 
5.3% in the vedolizumab study were in clinical remission (p<0.001, not evaluated in the 
golimumab study). This trend was previously observed in randomized-withdrawal studies in 
patients with Crohn’s disease,6 suggesting that it is a characteristic of ustekinumab induction 
treatment and not related to a unique aspect of the UC study population.  
Because of these differences in carryover effects, the “placebo” groups in the re-randomized 
maintenance studies cannot serve as a common comparator. They are not true placebo groups, 
because they consist of patients who responded to different induction treatments and were 
evaluated after receiving placebo maintenance. Thus, t e NMA of re-randomized maintenance 
studies underestimated the incremental benefit that ustekinumab maintenance provided over 
placebo and therefore relative to other treatments. The difference between ustekinumab and 
placebo maintenance did not reach statistical significa ce in the NMA (odds ratio [95% 
confidence interval] 2.46 [0.61,9.88] for clinical remission and 2.62 [0.95,7.23] for endoscopic 
improvement], eTable 2B). These estimates directly contradict the actual results from the UNIFI 
study, in which differences between ustekinumab and placebo maintenance were both 
statistically significant and clinically meaningful.2 The failure to corroborate the original results 
from this large, prospective, randomized, pivotal sudy underscores the flawed methodology of 
this NMA.  
Overall, the NMA of re-randomized maintenance studies was based on a thin network of 6 trials 
and 4 UC treatments versus placebo, and the results indicate that the network contained 
substantial heterogeneity. For each direct comparison of clinical remission in the pairwise meta-
analysis (MA) (Supplemental Figure 5A), the corresponding odds ratio in the NMA has a much 
wider confidence interval (eTable 2B). One would exp ct the NMA not to have such wide 
confidence intervals, since it can draw from the whole network to estimate the heterogeneity 
variance. However, the comparison between the pairwise MA and the NMA is difficult to 
interpret because the pairwise MA used the Mantel-Haenszel fixed-effect method, and the 
assumptions used in the software to estimate the heterogeneity variance in the NMA were not 








have been more informative, along with a detailed dscription of the NMA methods and 
publication of the code used in the analysis. 
Heterogeneity in randomized-withdrawal trial design can be accounted for by recalculating data 
to mimic a treat-through design, maintaining the initial randomized treatment groups from 
induction, accounting for initial and delayed responders to induction treatment, and using true 
placebo as a common comparator. Welty et al7 used this approach in an NMA of UC studies and 
found that ustekinumab had greater probabilities of clinical response, clinical remission, and 
endoscopic improvement through 1 year in patients who had not failed biologics than 
adalimumab, vedolizumab, golimumab, and infliximab. This approach allowed use of a larger 
network that consisted of studies with treat-through designs as well as studies with randomized-
withdrawal designs. Notably, even when VARSITY data8 were excluded from that NMA, the 
comparison of vedolizumab versus adalimumab showed a similar direction to VARSITY, further 
supporting the validity of the NMA methodology.   
The underlying assumptions in the NMAs of Singh et al have important implications for 
treatment of patients with ulcerative colitis. The results were used to formulate the recently 
published practice guidelines from the American Gastroenterology Association.9 Payors may use 
them to inform formulary decisions that limit patients’ access. NMAs are valuable in the absence 
of direct comparisons of treatments in head-to-head tri ls, but assumptions implicit in their 
design must be rigorously scrutinized. 
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